Steven Katz, MD, on Assessing New Delivery Methods for CAR T-Cell Therapy
The chief medical officer of Trisalus Life Sciences discussed studies evaluating the company’s PEDD system.
“We've studied this delivery technology with a broad range of different therapeutics. We’ve published data looking at delivery of chemoembolic beads, selective internal radiation therapy, CAR T-cell therapies, and now SD-101. We think this delivery technology has potential applicability to a wide range of therapies, including cell therapy and various forms of immunotherapy beyond that.”
Two common issues in treating solid tumors with cell therapies are immunosuppression in the tumor microenvironment and intratumoral pressure that makes it difficult to deliver sufficient concentrations of therapy to the tumor. Trisalus is hoping to combat these issues with its pressure-enabled drug delivery (PEDD) system along with its immunomodulatory therapy, SD-101.
Data on the PEDD system were presented by Steven Katz, MD, chief medical officer, Trisalus, and associate professor of surgery, Brown University, at the World Oncology Cell Therapy Congress (WOCTC) held April 25-26 in Boston, Massachusetts.1 CGTLive spoke with Katz to learn more about the PEDD system, an FDA-cleared interventional radiology catheter system and SD-101, the immunomodulatory therapy, is a toll-like receptor 9 agonist.
Katz discussed studies evaluating PEDD with different delivery products, including Sorrento Therapeutics’ carcinoembryonic antigen (CEA)-targeting chimeric antigen receptor (CAR) T-cell therapy (NCT04037241). While the approach seemed to show positive data, the trial has since been discontinued, and Sorrento Therapeutics recently filed for chapter 11 bankruptcy.2 He also touched on SD-101’s phase 1 trials in primary liver cancers, liver metastases, and primary pancreatic cancers.
Click here to read more coverage of WOCTC 2023.
